Quasi-Drugs in Japan
In Japan, cosmetic products are regulated by the Pharmaceutical and Medical Device Act, which stipulates compliance requirements and defines two categories of products: cosmetics and quasi-drugs. Quasi-drugs are in between pharmaceuticals and cosmetics, having officially recognized active ingredients. At the end of 2020, the MHLW proposed amendments for the marketing approval standards of medicated oral-care products, hair dyes and permanent wave agents, which were approved and just became effective. The GMP Ministerial Ordinance and the new JSQI were also approved by the MHLW in 2021.

JAPANESE COSMETICS REGULATION

The Pharmaceutical and Medical Device Agency (PMDA, an independent agency) and the Ministry of Health, Labour and Welfare (MHLW) are the entities that regulate cosmetic products made available in the Japanese market. Together, they assess the safety and efficacy of quasi-drugs and cosmetic products. Since 2014, the Pharmaceutical and Medical Device Act (PMD Act) is the regulation that applies to these products, replacing the former Japanese Pharmaceutical Affairs Law (JPAL). It sets requirements of regulatory compliance for cosmetics and quasi-drugs, defining and differentiating these two categories.

According to the Japanese regulation, cosmetics are “articles with mild action on the human body, which are intended to be applied to the human body through rubbing, sprinkling or other methods, aiming to clean beautify and increase the attractiveness, alter the appearance or to keep the skin or hair in good condition”. Examples of products considered cosmetics are: perfume and eau de cologne; make-up; skin care; hair care; soaps; special purpose cosmetics like sunscreen and shaving cream.

Quasi-drugs have officially recognized active ingredients and are defined as products that: prevent nausea and other discomforts; prevent heat rash, soreness, etc.; encourage hair growth or removing hair; exterminate and prevent mice, flies, mosquitoes, fleas, and others. Products like deodorants, depilatories, hair growth treatments, hair dyes, perm and straightening products, and medicated cosmetics (whitening, anti-aging, anti-acne and oily skin products) are considered quasi-drugs in this country. Quasi-drugs have certain limitations as to how much of an ingredient can be added to formulation.

Although the application process for product compliance is similar for cosmetics and quasi-drugs, there are stricter requirements for quasi-drugs and, by inherence, to its importers. Importers are responsible for all quality assurance and product liability. They need to acquire a specific license (“cosmetics manufacturing and sales license”) and to import a quasi-drug the importer needs to be appointed as a drug marketing authorization holder (MAH).

The information on the labelling of both cosmetic products and quasi-drugs must be in Japanese, clearly and explicitly indicated. False and misleading information or expressions and unapproved claims of effect-efficacy are prohibited.

QUASI-DRUGS NEW LEGAL REQUIREMENTS

The MHLW officially approved the Ministerial Ordinance on the Good Manufacturing Practice for Quasi-Drugs and Pharmaceuticals (GMP Ministerial Ordinance). It refined the compliance requirements for the manufacturing and quality management of the manufacturing facilities of pharmaceuticals and quasi-drugs.

In March 2021, the Japanese Standards of Quasi-drug Ingredients (JSQI 2021) was introduced, laying down new quasi-drug application rules and new permitted quasi-drug additives list, amending the JSQI 2006.

In July 2021, the marketing approval standards of medicated oral-care products, hair dyes and permanent wave agents became effective, approving the proposed amendments presented in the end of 2020 by the MHLW.

One of the amendments was the modification of the list of permitted additives in quasi-drugs. The medicated oral-care products were re-classified from two to three different classes and new regulations were stipulated regarding the types, specifications and dosages of active ingredients in the new class. There were also modifications on the specifications of active ingredients in hair colouring agents and permanent wave agents.

Entering different markets and being in compliance with a foreign country’s cosmetics regulation can be a hard task. If you need more information on this or other subjects, do not hesitate to contact us at info@criticalcatalyst.com.

References:

  1. Japan Revises the Approval Requirements for Quasi-drugs. Chemlinked. Jul 07, 2021. Available from: https://cosmetic.chemlinked.com/news/cosmetic-news/japan-revises-the-approval-requirements-for-quasi-drugs?utm_source=edm
  2. Japan Revises the Standards for Marketing Approval of Some Quasi-drugs. Chemlinked. Dec 14, 2020. Available from: https://cosmetic.chemlinked.com/news/cosmetic-news/japan-revises-the-standards-for-marketing-approval-of-some-quasi-drugs
  3. Breaking! Japan Implements the New Japanese Standards of Quasi-drug Ingredients (JSQI 2021). Chemlinked. Apr 16, 2021. Available from: https://cosmetic.chemlinked.com/news/cosmetic-news/breaking-japan-implements-the-new-japanese-standards-of-quasi-drug-ingredients-jsqi-2021

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »